Glymphatic Reserve as a Determinant of Responsiveness Neuro-Metabolic Rehabilitation Driven by GLP-1 Receptor Agonists: A Novel Paradigm for Managing Alzheimer’s Disease as Type 3 Diabetes in Central Asia

RIntroduction: Alzheimer’s disease (AD) and related neurodegenerative disorders represent a rapidly escalating public health crisis globally and within Central Asia, severely impacting aging populations and health system sustainability. Emerging evidence conceptualizes AD as “Type 3 Diabetes,” characterized by brain-specific insulin resistance, impaired cerebral glucose metabolism, and chronic neuroinflammation. Standard neuroprotective therapies offer limited long-term efficacy, underscoring the critical need for novel, multidisciplinary clinical frameworks that address upstream metabolic triggers. Hypothesis: We propose “Neuro-Metabolic Rehabilitation” as a distinct clinical paradigm that utilizes early pharmacological intervention with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) combined with structured metabolic lifestyle modificationsto restore central insulin signaling, optimize cerebral glucose utilization, and mitigate neurodegenerative progression. Testing the Hypothesis: We suggest multicenter randomized controlled trials in Central Asian populations comparing standard neurological care with integrated neuro-metabolic rehabilitation programs utilizing GLP-1 RAs, measuring changes in cognitive scores, peripheral insulin resistance, and central neuroinflammatory biomarkers. Implications: We propose a comprehensive conceptual framework, “neuro-metabolic rehabilitation,” that shifts physical, nutritional, and metabolic medicine from supportive roles to central, disease-modifying interventions within multidisciplinary dementia care tailored to Central Asian populations.